AAPL 189.07 +0.3 (+0.16%)MSFT 117.02 -0.72 (-0.62%)FB 167.35 +1.05 (+0.63%)ZNGA 5.3 -0.01 (-0.19%)NVDA 175.17 +1.31 (+0.75%)WBA 61.7 +0.14 (+0.23%)GOOG 1184.77 -8.35 (-0.70%)PIH 5.45 -0.16 (-2.85%)
AAPL 189.07 +0.3 (+0.16%)MSFT 117.02 -0.72 (-0.62%)FB 167.35 +1.05 (+0.63%)ZNGA 5.3 -0.01 (-0.19%)NVDA 175.17 +1.31 (+0.75%)WBA 61.7 +0.14 (+0.23%)GOOG 1184.77 -8.35 (-0.70%)PIH 5.45 -0.16 (-2.85%)

Balance Sheet ABUS Quote Arbutus Bio

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
CashAndCashEqui 23 54 37
ShortTermInvest 107 72 88
Cash 131 126 125
AccountReceivab 0 0 1
Inventories 0 0 0
DeferredIncomeT 0 0 0
OtherCurrentAss 0 0 0
TotalCurrentAss 133 129 129
PPE 18 25 17
AccumulatedDepr -11 -13 -7
NetPPE 7 12 10
EquityAndOtherI 0 0 22
Goodwill 24 24 22
IntangibleAsset 99 59 44
OtherLTAssets 13 13 0
TotalNonCurrent 143 108 99
TotalAssets 276 237 228
ShortTermDebt 0 0 0
AccountsPayable 3 2 3
TaxesPayable 0 0 0
AccruedLiabilit 6 9 8
DeferredRevenue 0 3 0
OtherCurrentLia 1 1 0
TotalCurrentLia 11 15 11
Debt 12 12 0
DeferredTaxesLi 41 17 13
DeferredRevenue 0 0 0
OtherLTLiabilit 9 11 4
TotalNonCurrent 62 40 16
TotalLiabilitie 73 55 28
CommonStock 0 0 0
AdditionalPaidI 904 919 927
RetainedEarning -651 -738 -805
AccumulatedOthe -50 -48 -48
TotalStockholde 203 182 200
TotalLiabilitie 276 237 228
Arbutus Biopharma Corporation income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Arbutus Biopharma Corporation FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.